

### List of Abbreviations

% CDR	Percentage cumulative drug release
%	Percentage
% RSD	Percentage relative standard deviation
% EE	Percent entrapment efficiency
% w/w	Percentage weight by weight
% v/v	Percentage volume by volume
% w/v	Percentage weight by volume
<	Less than
≤	Less than equal to
>	More than
≥	More than equal to
~	Approximately equal to
±	Plus or minus
=	Equal to
$\lambda_{\max}$	Wavelength of maximum absorbance
g	Gram
mg	Milligram
°C	Degree centigrade
$\mu\text{m}$	Micrometer
$\mu\text{L}$	Microliter
cm	Centimeter
mL	Milliliter
nm	Nanometer
ng/mL	Nanogram per milliliter
$\mu\text{g}/\text{mL}$	Micrometer per milliliter
mg/mL	Milligram per milliliter
G'	Storage modulus
G''	Loss modulus
ANOVA	Analysis of variance
ACN	Acetonitrile
FTIR	Fourier transform infrared spectrometer
API	Active pharmaceutical ingredient
DMSO	Dimethyl sulfoxide
C <sub>max</sub>	Maximum concentration
AUC	Area under curve
BSA	Bovine serum albumin
CPCSEA	Committee for the purpose of control and supervision of experiments on animals
Conc.	Concentration
CP	Clobetasol propionate
VD3	Vitamin D3
CoQ10	Coenzyme Q10
DSC	Differential scanning calorimetry
FESEM	Field emission scanning electron microscopy
DLS	Dynamic light scattering

h	Hour
EDTA	Ethylene diamine tetra acetic acid
GC-HS	Gas chromatography - Headspace
RP-HPLC	Reverse phase - High performance liquid chromatography
IPA	Isopropyl alcohol
HETP	Height equivalent to theoretical plates
HQC	Higher quality control sample
ICH	International council for harmonization
IAEC	Institutional animal ethical committee
IL	Interleukin
IS	Internal standard
LOQ	Limit of quantification
LLOQ	Lower limit of quantification
LOD	Limit of detection
MeOH	Methanol
MDA	Malondialdehyde
LQC	Lower quality control
MRI	Magnetic resonance imaging
min	Minute
mPEG	Methoxy (polyethylene glycol)
MQC	Medium quality control
mPEG-PLA	Methoxy (polyethylene glycol)-(polylactide)
NMR	Nuclear magnetic resonance
MWCO	Molecular weight cut off
<i>p</i> value	Significance level in statistical tests
<i>n</i>	Diffusional exponent indicating the drug release mechanism in Korsmeyer-peppas model
LPNs	Lipid-polymer hybrid nanoparticles
pH	Negative log to the base 10 of hydrogen ion concentration
PLA	Poly (D,L-lactide)
PDI	Polydispersity index
$R_t$	Retention time
QC	Quality control
$R_s$	Resolution
$R^2$	Regression coefficient
SD	Standard deviation
rpm	Rotations per minute
SLNs	Solid-lipid nanoparticles
RT	Room temperature
sec	Second
PDC	Polymer drug conjugate
LPs	Liposomes
NLCs	Nanostructure lipid carriers
$t_{1/2}$	Half-life
SOD	Superoxide dismutase
HR-TEM	High resolution – Transmission electron microscopy

USFDA	United States Food and Drug Administration
TNF- $\alpha$	Tumor necrosis factor - $\alpha$
IMQ	Imiquimod
ZP	Zeta potential

---



---

## LIST OF TABLES

---



---

Table No.	Caption	Page No.
1.1	List of lipidic nanosystems explored topically for psoriasis management	18
1.2	List of polymeric nanosystems explored topically for psoriasis management	24
2.1	Chromatographic conditions for the CP methods	49
2.2	Intra-day and Inter-day precision and accuracy of analytical samples of CP	58
2.3	Intra-day and Inter-day precision and accuracy of CP spiked in skin extract	58
2.4	Intra-day and Inter-day precision and accuracy of CP in mice plasma	59
2.5	System suitability parameters for various methods	59
2.6	Robustness studies of CP	60
2.7	Chromatographic conditions for analytical methods	61
2.8	Intra-day and Inter-day precision and accuracy of analytical samples of VD3	66
2.9	Intra-day and Inter-day precision and accuracy of analytical samples of CoQ10	67
2.10	System suitability parameters	67
2.11	Robustness of analytical samples of VD3	68
2.12	Robustness of analytical samples of CoQ10	68
3.1	Composition of LPNs and their characterization for particle size, PDI, zeta potential and encapsulation efficiency (%). In addition to the composition provided, all batches contain clobetasol propionate (4 mg) and mPEG-PLA (60 mg) as amphiphilic copolymer	90
3.2	Systemic absorption of clobetasol propionate after topical application of Clobetamos™ gel or CP/LPNs-PL gel on the back of IMQ induced psoriatic mice	100

---

---

3.3	Various parameters indicating skin damage score after topical application of Clobetamos™ gel or CP/LPNs-PL gel on the right back of IMQ induced psoriatic mice	104
3.4	Various parameters indicating liver and spleen damage score after topical application of Clobetamos™ gel or CP/LPNs-PL gel on the right back of IMQ induced psoriatic mice	105
5.1	Improved total skin damage score of the right ear (ES) and back skin (BS) after topical application of CoQ10/LPNs gel compared to CoQ10 gel using IMQ-induced plaque psoriatic mice model	184
5.2	Improved total liver and spleen damage score after topical application of CoQ10/LPNs gel compared to CoQ10 gel using IMQ-induced plaque psoriatic mice model	185

---

---

---

**LIST OF FIGURES**

---

---

<b>Figure No.</b>	<b>Captions</b>	<b>Page No.</b>
1.1	Pathophysiology of psoriasis	5
1.2	Advantages of nano-carrier based drug delivery systems over conventional formulations	10
2.1	Representative chromatogram of (A) mobile phase spiked with formulation excipients and (B) analytical sample containing CP dissolved in ACN (45µg/mL)	55
2.2	Representative chromatogram of (A) blank skin extract, (B) zero i.e. IS (DTX) (Rt:7.77 min) spiked in the skin extract, (C) CP (Rt: 14.03 min) and DTX (Rt: 7.78 min) spiked in the skin extract at the concentration of 500 ng/mL and 250 ng/mL respectively, (D) blank plasma sample, (E) zero i.e. plasma sample spiked with IS and (F) plasma sample spiked with IS (Rt: 10.539 min) and CP (Rt: 20.445 min) at concentration of 300 ng/mL and 75 ng/mL respectively	56
2.3	Representative calibration curve of (A) CP in analytical samples, (B) skin extract samples spiked with CP and (C) plasma samples spiked with CP	57
2.4	Representative chromatogram of (A) mobile phase of VD3 spiked with formulation excipients, (B) analytical sample containing vitamin D3 dissolved in methanol (45µg/mL), (C) mobile phase of CoQ10 spiked with formulation excipients and (D) analytical sample containing CoQ10 dissolved in methanol (45µg/mL)	65

---

2.5	Calibration curve for (A) VD3 and (B) CoQ10 in methanol	66
3.1	Characterization CP/LPNs and CP/LPNs gel. (A) photographic images of undiluted and 100 X diluted CP/LPNs-PL, (B) particle size distribution of CP/LPNs-PL determined by Malvern zetasizer, (C and D) transmission electron microscopic images of CP/LPNs-PL and CP/LPNs-PL gel, (E, F, and G) scanning electron microscopic images of clobetasol propionate loaded gel (CP gel), CP/LPNs-PL and CP/LPNs-PL gel, and (H and I) shear stress versus shear rate and viscosity versus shear rate curves of CP/LPNs-PL gel	91
3.2	(A) FTIR spectra of pure CP, CP/LPNs-PL, CP/LPNs-PL gel, blank LPNs-PL and blank LPNs-PL gel and (B) DSC thermograms of pure CP, blank LPNs-PL, blank LPNs-PL gel, CP/LPNs-PL and CP/LPNs-PL gel	92
3.3	<i>In vitro</i> release of clobetasol propionate from (A) freshly prepared CP/LPNs gels and (B) CP/LPNs-PL gels stored for 3 months and 6 months at 2-8°C and room temperature (RT)	93
3.4	(A) Fluorescence microscopy and (B and C) flow cytometry analysis of cellular uptake following incubation with free Coumarin-6 (C6), C6 loaded LPNs-PL (C6/LPNs-PL) and C6/LPNs-PL with various endocytosis inhibitors for 4 h in HaCaT cells (Magnification 40X; Scale bar 200 $\mu$ m). A visible shift (in B) in the peak (towards right) in C6/LPNs-PL indicating higher internalization while a visible shift (in C) in the peak (towards left) in C6/LPNs-PL plus M $\beta$ CD or MST indicating lipid raft or caveolin mediated endocytosis, (D) Percent fluorescence intensity of HaCaT cells determined by flow cytometry	95

---

- 
- 3.5 (A) Microscopic images of HaCaT cells treated with free clobetasol propionate (CP) and CP/LPNs-PL (Magnification 40X; Scale bar 200  $\mu\text{m}$ ), (B, C and D) cell viability, apoptosis and cell cycle analysis of HaCaT cells treated with free CP and CP/LPNs-PL. For cell viability, each value is represented as mean  $\pm$  SD ( $n = 4$ ) and statistical analysis was performed using paired  $t$  test with significant difference of #,  $p < 0.01$  free CP versus CP/LPNs-PL 97
- 3.6 Ex vivo permeation of LPNs in psoriatic skin of *Swiss albino* mice. (A) Bio-imaging using IVIS spectrum of *ex vivo* psoriatic skin tissue treated with free C6 and C6/LPNs-PL gel after 6 h, 12 h and 24 h ( $n = 3$ ) and (B) Quantification of clobetasol propionate in the remaining skin i.e. viable epidermis and dermis after treatment with Clobetamos<sup>TM</sup> gel and CP/LPNs-PL gel. Each value is represented as mean  $\pm$  SD. #,  $p < 0.01$  versus Clobetamos<sup>TM</sup> gel (0.05% w/w) group 98
- 3.7 CP/LPNs-PL gel inhibited IMQ-induced psoriasis-like skin condition in *Swiss albino* mice ( $n = 6$ ). (A to C) Scoring of erythema, scaling, and thickening based on the clinical Psoriasis Area and Severity Index (PASI) measured on scale from 0-4, (D) cumulative score indicating the extent of psoriatic inflammation on scale from 0-12, (E) back skin thickness measured using digital vernier caliper, (F) percent change in body weight, (G) Comparative thickness of right and left ear measured using digital micrometer, (H) Average spleen weights for different treatment groups, and comparison of spleen size of treatment groups viz. (a) negative control, (b) positive control, (c) Clobetamos<sup>TM</sup> gel (0.05% w/w), (d) CP/LPNs-PL gel (0.025% w/w), (e) CP/LPNs-PL 101
-



- 
- gel (0.05% w/w). Each value is represented as mean  $\pm$  SEM. \*,  $p < 0.05$  and #,  $p < 0.01$ , versus Clobetamos<sup>TM</sup> gel (0.05% w/w) group
- 3.8 IMQ-induced skin inflammation phenotypically simulates psoriasis like skin condition. Swiss albino mice were treated with Imiquad@ (5% w/w) on the shaved back skin and right ear on daily basis. (A) Experimental protocol for IMQ-induced psoriasis like mouse model, (B) phenotypical presentation of mouse back skin after 5 days of different treatments, (C) histopathological (H&E staining) evaluation of right ear skin (ES), back skin (BS), liver and spleen of animals at the end of the study. For **ES** and **BS** abbreviations are as follow- **RED Arrow:** Epidermis; **Plain green arrow:** Dermis; **Black arrow:** Stratum corneum; **Yellow Arrow:** Infiltration of inflammatory Cells; **Blue Arrow:** Capillary proliferation; **Orange Arrow:** Epidermal hyperplasia. For **liver** abbreviations are as follow- **RED Arrow:** Hepatocytes; **Black arrow:** Infiltration of mononuclear inflammatory Cells **Yellow Arrow:** Hepatocytes degeneration; **Blue Arrow:** Central vein. For **spleen** abbreviations are as follow- **RED Arrow:** White pulp; **Black arrow:** Splenic central artery **Yellow Arrow:** Red pulp; **Blue Arrow:** Depopulation of lymphocytes in white pulp. (Magnification: 40X). Scale bar = 50  $\mu$ m
- 3.9 (A) Immunohistochemically stained psoriatic back skin sections of mice for Ki-67, cell proliferation marker. CP/LPNs-PL gel treatment could effectively decrease the expression of Ki-67 (Magnification: 40X). Black arrow represents the overexpression of Ki-67. Scale bar = 50  $\mu$ m. (B) average Ki-67 positive cells per High Power Field (HPF)
-

- 
- of different treatment groups. Each value is represented as mean  $\pm$  SD.
- #,  $p < 0.001$  versus Clobetamos<sup>TM</sup> gel (0.05% w/w)
- 4.1 Characterization of VD3/LPNs. (A) Dynamic light scattering (DLS) 141  
measurements of size distribution of freshly prepared VD3/LPNs (red plot) and VD3/LPNs stored at room temperature for one day (green plot) in water determined by Malvern zetasizer, (B) photographic images of (a) VD3/LPNs dispersion and (b) VD3/LPNs gel (0.005% w/w), (C) field emission-scanning electron microscopic images of VD3/LPNs (scale bar = 1  $\mu$ m), and (D) In vitro drug release from VD3/LPNs showing a sustained release profile compared to its free form i.e. free VD3. Error bars indicate mean  $\pm$  SD
- 4.2 (A) FTIR spectra of pure VD3, VD3/LPNs, VD3/LPNs gel, blank 142  
LPNs and blank LPNs gel and (B) DSC thermograms of pure VD3, blank LPNs, blank LPNs gel, VD3/LPNs and VD3/LPNs gel
- 4.3 Rheological and oscillatory rheological measurements of VD3/LPNs 144  
gel suggested non-newtonian flow properties possessing shear-thinning behaviour with variable thixotropy as apparent from (A) shear stress (mPa) versus shear rate (1/s) and (B) viscosity ( $\eta$ ) versus shear rate (1/s) graphs, (C) subjected to rise in temperature did not show sudden collapse of gel 3D matrix structure evident from viscosity (mPa.s) versus temperature ( $^{\circ}$ C) graph suggesting stability of matrix, (D) formation of viscoelastic gel with  $G'$  (storage modulus)  $>$   $G''$  (loss modulus) within the LVE region in amplitude sweep test, and (E) long term storage stability was predicted from frequency sweep test where  $G' > G''$  in lower frequency range
-

- 
- 4.4 VD3/LPNs gel suppressed IMQ-induced inflammatory psoriatic condition in mice. Scores of various psoriatic parameters based on PASI system measured on scale from 0-4 on the days indicated that includes (A) erythema, (B) scaling, and (C) thickening, Additionally (D) cumulative score representing the degree of psoriasis that includes sum of erythema, scaling and thickening measured on scale from 0-12 on the days indicated. Each value is denoted as mean  $\pm$  SEM. @,  $p \leq 0.05$  and \$,  $p \leq 0.01$ , versus VD3 gel (0.005% w/w) treated group 145
- 4.5 IMQ-induced psoriatic mouse model resembles the clinical psoriasis condition. Swiss albino mice were subjected to topical treatment on daily basis with IMQ on the right ear and back skin. (A) In vivo study protocol for IMQ-induced psoriatic mice model, (B) photographic images of back skin of mouse from various groups on day 0 and day 5, measurement of (C) back skin (BS) and (D) right ear (ES) thickness using digital vernier caliper and micrometer respectively. Each value is denoted as mean  $\pm$  SEM. @,  $p \leq 0.05$  and \$,  $p \leq 0.01$ , versus VD3 gel (0.005% w/w) treated group 147
- 4.6 Topical treatment with IMQ results into enlargement of spleen shown in positive control group. VD3/LPNs gel showed significant reduction in the spleen weights. (A) Average spleen weights from various groups, along with their comparative spleen size s viz. (a) negative control, (b) positive control, (c) VD3 gel (0.005% w/w), (d) VD3/LPNs gel (0.0025% w/w), (e) VD3/LPNs gel (0.005% w/w). During the study duration, application of IMQ leads to substantial toxicity resulting into fluctuation in body weights with significant 148
-

- 
- reduction in the values from their original ones. (B) percent change in body weight indicating complete recovery in groups treated with VD3/LPNs gel. Each value is denoted as mean  $\pm$  SEM. @,  $p \leq 0.05$  and \$,  $p \leq 0.01$ , versus VD3 gel (0.005% w/w) treated group
- 4.7 (A) Histopathological examination (H&E, Magnification: 40X) of right ear skin (ES) and back skin (BS) of animals from various groups. For **ES** and **BS**, arrow acronyms are as follow- **Black:** Epidermis; **Pink:** Pustule of Kogoj; **Dark green:** Dermis; **Sky blue:** Munro microabscess; **Red:** Infiltration of inflammatory Cells; **Blue:** Stratum Corneum; **Yellow:** Capillary Proliferation; **White:** Parakeratosis; **Purple:** Epidermal Hyperplasia; **Fluorescent green:** Hyperkeratosis. Scale bar = 50  $\mu$ m and (B) Assessment of various psoriatic parameters representing total skin damage score for both right ear and back skin of various groups 150
- 4.8 (A) Histopathological examination (H&E) of liver and spleen of animals from various groups. For **liver** (Magnification: 40X), arrow acronyms are as follow- **Red:** Infiltration of mononuclear inflammatory Cells; **Green:** Hepatocytes; **Yellow:** Central vein; **Orange:** Hepatocytes degeneration. For **spleen** (Magnification: 10X), arrow acronyms are as follow- **Green:** White pulp; **Red:** Red pulp. Scale bar = 50  $\mu$ m and (B) Assessment of various psoriatic parameters representing sum of total liver and spleen damage scores of various groups 151
- 4.9 (A) Immunohistochemical staining of Ki67, cell proliferation marker expressed in back skin sections of psoriatic mice. Treatment with 152
-

- 
- VD3/LPNs gel efficiently downregulates Ki67 expression (Magnification: 40X, Scale bar = 50  $\mu$ m). Blue arrow exemplifies the upregulation of Ki67 expression. (B) distribution of average cells positive for Ki67 per High Power Field (HPF) among various groups indicating effectiveness of VD3/LPNs in ameliorating psoriasis. Each value is denoted as mean  $\pm$  SEM. @,  $p \leq 0.05$  and \$,  $p \leq 0.01$ , versus VD3 gel (0.005% w/w) treated group
- 5.1 Physicochemical characterization of monolithic CoQ10 loaded polymer-lipid hybrid nano-carrier (CoQ10/LPNs). (A) Schematic representation of CoQ10/LPNs along with the particle size distribution demonstrating unimodal size distribution with mean hydrodynamic diameter of 121 nm and polydispersity index of 0.252 determined by dynamic light scattering (Malvern Nano ZS), (B) FE-SEM image showing uniform and spherical morphology, (C) In vitro drug release profile of CoQ10 from CoQ10/LPNs exhibiting sustained drug release without any burst release (n = 3, Mean  $\pm$  SD) 174
- 5.2 (A) FT-IR spectra of CoQ10, CoQ10/LPNs, CoQ10/LPNs gel, blank LPNs and blank LPNs gel and (B) DSC thermograms of CoQ10, CoQ10/LPNs and CoQ10/LPNs gel, blank LPNs and blank LPNs gel 175
- 5.3 Rheological measurements and oscillatory rheological analysis of CoQ10/LPNs gel indicated non-newtonian type system with pseudoplastic properties and variable thixotropy (A) Viscosity ( $\eta$ ) against shear rate (1/s) and (B) shear stress against shear rate (1/s) graphs, (C) stability of gel 3D matrix evident from the graph of viscosity ( $\eta$ ) against temperature ( $^{\circ}$ C) demonstrating no sudden 176
-

- 
- collapse of viscosity (mPa.s) with rise in temperature ( $^{\circ}\text{C}$ ), (D) amplitude sweep test data indicating viscoelastic gel formation with  $G' > G''$  within the linear viscoelastic (LVE) region wherein  $G'$  is storage modulus and  $G''$  is loss modulus, (E) frequency sweep test data suggesting long term storage stability as obvious from higher storage modulus than loss modulus ( $G' > G''$ ) in lower frequency region
- 5.4 Schematic representation of study protocol for conducting IMQ-induced in vivo anti-psoriatic efficacy studies along with representative photographic presentation of back skin of animals from various groups on day 0 and day 5 178
- 5.5 CoQ10/LPNs gel reduces the PASI scores and ameliorated the skin lesion of IMQ-induced plaque psoriatic mouse model in Swiss albino mice ( $n = 6$ ). Antipsoriatic efficacy was evaluated based on PASI scores measured on a scale from 0 to 4 for parameters (erythema, scaling, and thickening) and from 0 to 12 for cumulative score (summation of erythema + scaling + thickening) which served as an index of extent of psoriasis induced. Data is presented as mean  $\pm$  SEM. #,  $p \leq 0.05$  and @,  $p \leq 0.01$ , versus CoQ10 gel (0.06% w/w) treated group 179
- 5.6 CoQ10/LPNs gel substantially inhibited the rise in skin thickness induced by topical application of IMQ. Commercial product of IMQ (Imiquad® (5% w/w)) was applied topically onto the right ear and back skin of Swiss albino mice for 5 consecutive days and resulted into thickening of the skin tissue due to underlying dermal 180
-

- 
- inflammatory cascade accompanied by hyperplasia of keratinocytes. Bringing back the thickness to normal or suppressing the rise in the thickness marked the efficiency of treatment. Measurement of the (A) average right ear thickness and (B) average back skin thickness for various groups using digital micrometer and vernier caliper on the indicated days. Symbols represented average thickness  $\pm$  SEM (n = 6). Data is presented as mean  $\pm$  SEM. #,  $p \leq 0.05$  and @,  $p \leq 0.01$ , versus CoQ10 gel (0.06% w/w) treated group
- 5.7 Topical application of IMQ exhibited toxicity by inducing splenomegaly and body weight fluctuation (reduced body weights). CoQ10/LPNs gel showed improved recovery w.r.t. both spleen weights and body weights. (A) Average spleen weights of various treatment groups, along with their comparative spleen sizes viz. (a) negative control, (b) positive control, (c) CoQ10 gel (0.06% w/w), (d) CoQ10/LPNs gel (0.03% w/w), (e) CoQ10/LPNs gel (0.06% w/w) and (B) percent change in body weight indicating improved recovery in groups treated with CoQ10/LPNs gel on Day 5. Data is presented as mean  $\pm$  SEM. #,  $p \leq 0.05$  and @,  $p \leq 0.01$ , versus CoQ10 gel (0.06% w/w) treated group 181
- 5.8 Comparative histological alterations in various tissues such as right ear skin (ES), back skin (BS), liver and spleen suggesting effectiveness of CoQ10/LPNs gel in reduction of inflammatory infiltration leading to suppression of keratinocyte hyperplasia in IMQ-induced plaque psoriatic mouse model that simulates the clinical psoriasis. Commercial product of IMQ (Imiquad® (5% w/w)) was 183
-

---

topically applied onto the ES and BS of Swiss albino mice for 5 consecutive days that resulted into development of psoriasis-like inflammatory skin condition characterized by dermal damage (rete ridges, acanthosis, hyperplasia, parakeratosis, inflammatory infiltrate etc.), liver damage (fibrosis) and spleen damage (undifferentiated white pulp and red pulp). For ES and BS (Scale bar = 50  $\mu$ m at 40X magnification) arrow abbr. are as follow- Red: Dermis; Blue: Epidermis; Black: Inflammatory infiltrates; Dark green: Stratum Corneum; Pink: Capillary Proliferation; White: Hyperkeratosis; Fluorescent green: Parakeratosis; Yellow: Epidermal Hyperaplasia. For liver (Scale bar = 50  $\mu$ m at 40X magnification) arrow abbr. are as follow- Orange: Inflammatory infiltrates; Black: Hepatocytes; Green: Central Vein; Red: Hepatocytes Degeneration. For spleen (Scale bar = 50  $\mu$ m at 40X magnification) arrow abbr. are as follow- White: Red Pulp; Black: White Pulp

- 5.9 Ki67 (cell proliferating nucleoprotein) is found to be over-expressed in psoriatic lesions. (A) Immunohistochemical staining of Ki67 expressed in back skin of negative control or IMQ-induced psoriatic mice without or with treatment of CoQ10 containing formulations. CoQ10/LPNs gel resulted into significant reduction in expression of Ki67 which is over-expressed in psoriatic lesions. (Scale bar = 50  $\mu$ m at 40X magnification). Red arrow signifies the higher expression of Ki67, (B) Graphs of average keratinocytes positive for Ki67 per High Power Field (HPF) of various groups indicated treatment with CoQ10/LPNs gel significantly reduced expression of cell proliferation



marker and results were in alignment with the PASI scores. Data is presented as mean  $\pm$  SD. #,  $p \leq 0.05$  and @,  $p \leq 0.01$ , versus CoQ10 gel (0.06% w/w) treated group

- 5.10 Comparative assessment of various groups w.r.t. (A) MDA and (B) GSH levels suggesting marked improvement in the antioxidant effect of CoQ10 when delivered as LPNs gel 187
-